drugset / Trial / NCT06135675
PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia
Phase 1/2
Completed
36 enrolled
TenNor Therapeutics Inc.
The First Hospital of Jilin University · collab
RandomizedSequentialDouble-blindTreatment
Summary
The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.
Timeline
- Start
- 2020-08-27
- Primary completion
- 2021-06-16
- Completion
- 2021-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RIFAQUIZINONE | Small molecule | 100 mg | Oral |
| Subject | RIFAQUIZINONE | Small molecule | 300 mg | Oral |
| Subject | RIFAQUIZINONE | Small molecule | 600 mg | Oral |
Indications
No indication recorded.